CMS MolDX grants fourth Medicare coverage decision for Personalis’ NeXT Personal MRD test in breast cancer monitoring
- Coverage expansion reimburses use of NeXT Personal MRD to monitor neoadjuvant therapy response in Stage II–III triple-negative and HER2-positive breast cancer.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.